Health

WHO recommends COVID-19 drug and urges transparency around pricing

New York: A highly successful COVID-19 therapy must be made available to more people, the World Health Organization (WHO) has said, calling for wider distribution and greater transparency surrounding its pricing. more

Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults aged between 18-55

New York: Pfizer Inc and BioNTech SE on Wednesday announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidat ...

Study shows Pfizer, AstraZeneca COVID-19 vaccines less effective against Omicron strain: WHO

Geneva/UNI/Sputnik: Preliminary results of a non-peer-reviewed study from the United Kingdom indicate reduced effectiveness of the Pfizer and AstraZeneca vaccines against the Omicron coro ...

Pfizer seeks emergency use authorization for COVID-19 oral antiviral candidate

Washington: Pfizer Inc. on Tuesday announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID, for the treatment of mild to modera ...

Pfizer COVID-19 antiviral pill shows it cuts risks of hospitalization, death by 89 percent

Pharmaceutical giant Pfizer Inc on Friday announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID, significantly reduced hospitalization and death, based on an inte ...

Benefits of Pfizer Covid-19 vaccine for children surpass risks: US Drug Regulator

Washington/UNI/Sputnik: The benefits expected from the Pfizer Covid-19 vaccine shots for children between 5 and 11 years old outweigh the risks of side effects, the US Food and Drug Admin ...

Study shows two doses of Pfizer-BioNTech vaccine are highly effective against COVID-19 hospitalizations for at least six months

New York: Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from ...

Pfizer COVID-19 vaccine is safe for children aged between 5 to 11, show Clinical trial results

New York: Pfizer Inc and BioNTech SE on Monday announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 y ...

New Zealand reports first death due to anti-COVID-19 Pfizer vaccine

Auckland/IBNS: New Zealand has reported its first death due to an anti-COVID-19 Pfizer vaccine, the country's health ministry stated.

Vaccine antibody levels start to wane at around 2-3 months: Study

London: Total antibody levels appear to start declining from as early as six weeks after complete vaccination and can reduce by more than 50% over 10 weeks, according to new data from UCL ...